336 related articles for article (PubMed ID: 15623613)
1. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Chao A; Wyre HW; Hylind LM; Giardiello FM; Yang VW
Clin Cancer Res; 2004 Dec; 10(24):8357-62. PubMed ID: 15623613
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Schmotzer B; Easley KA; Hylind LM; Giardiello FM; Yang VW
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2366-9. PubMed ID: 16214918
[TBL] [Abstract][Full Text] [Related]
3. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis.
Giardiello FM; Casero RA; Hamilton SR; Hylind LM; Trimbath JD; Geiman DE; Judge KR; Hubbard W; Offerhaus GJ; Yang VW
Gastroenterology; 2004 Feb; 126(2):425-31. PubMed ID: 14762779
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
5. Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients.
Koornstra JJ; Rijcken FE; Oldenhuis CN; Zwart N; van der Sluis T; Hollema H; deVries EG; Keller JJ; Offerhaus JA; Giardiello FM; Kleibeuker JH
Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1608-12. PubMed ID: 16030090
[TBL] [Abstract][Full Text] [Related]
6. Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial chemoprevention of intestinal neoplasia.
Torrance CJ; Jackson PE; Montgomery E; Kinzler KW; Vogelstein B; Wissner A; Nunes M; Frost P; Discafani CM
Nat Med; 2000 Sep; 6(9):1024-8. PubMed ID: 10973323
[TBL] [Abstract][Full Text] [Related]
8. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
[TBL] [Abstract][Full Text] [Related]
9. [Chemoprevention of familial cancer].
Ishikawa H
Gan To Kagaku Ryoho; 1997 Jun; 24(8):951-7. PubMed ID: 9212803
[TBL] [Abstract][Full Text] [Related]
10. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism.
Brosens LA; Iacobuzio-Donahue CA; Keller JJ; Hustinx SR; Carvalho R; Morsink FH; Hylind LM; Offerhaus GJ; Giardiello FM; Goggins M
Clin Cancer Res; 2005 Jun; 11(11):4090-6. PubMed ID: 15930344
[TBL] [Abstract][Full Text] [Related]
11. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
[TBL] [Abstract][Full Text] [Related]
12. Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposis.
Yang VW; Geiman DE; Hubbard WC; Spannhake EW; Hylind LM; Hamilton SR; Giardiello FM
Prostaglandins Other Lipid Mediat; 2000 Jan; 60(1-3):83-96. PubMed ID: 10680778
[TBL] [Abstract][Full Text] [Related]
13. [Treatment with sulindac of adenomatous polyps in familial polyposis].
Cerdán FJ; Torres-Melero J; Martínez S; Gutiérrez del Olmo A; Balibrea JL
Rev Esp Enferm Dig; 1995 Aug; 87(8):574-6. PubMed ID: 7577106
[TBL] [Abstract][Full Text] [Related]
14. Detoxification enzyme polymorphisms are not involved in duodenal adenomatosis in familial adenomatous polyposis.
Berkhout M; Roelofs HM; te Morsche RH; Dekker E; van Krieken JH; Nagengast FM; Peters WH
Br J Surg; 2008 Apr; 95(4):499-505. PubMed ID: 18161889
[TBL] [Abstract][Full Text] [Related]
15. [Sulindac in familial adenomatous polyposis coli--preliminary findings of a prospective study].
Müller A; Hürlimann R; Meyenberger C; Staub P; Kobler E; Ammann R
Schweiz Med Wochenschr; 1994 Apr; 124(15):651-4. PubMed ID: 8191270
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.
Hisamuddin IM; Yang VW
Pharmacogenomics; 2007 Jun; 8(6):635-43. PubMed ID: 17559352
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis.
Giardiello FM; Spannhake EW; DuBois RN; Hylind LM; Robinson CR; Hubbard WC; Hamilton SR; Yang VW
Dig Dis Sci; 1998 Feb; 43(2):311-6. PubMed ID: 9512123
[TBL] [Abstract][Full Text] [Related]
18. In vivo variability of TMA oxidation is partially mediated by polymorphisms of the FMO3 gene.
Lambert DM; Mamer OA; Akerman BR; Choinière L; Gaudet D; Hamet P; Treacy EP
Mol Genet Metab; 2001 Jul; 73(3):224-9. PubMed ID: 11461189
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of carcinogenesis in familial tumors.
Ishikawa H
Int J Clin Oncol; 2004 Aug; 9(4):299-303. PubMed ID: 15375706
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention with special reference to inherited colorectal cancer.
Lynch PM
Fam Cancer; 2008; 7(1):59-64. PubMed ID: 17680350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
